Tagged with Pharm

France France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition. With Brexit uncertainties across the channel and populist tendencies souring the prospects of some of its neighbours, France – under…

France Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of the natural health product market and the role it can play as a partner to preventative care and healthcare sustainability.…

Opinion Meghann Chilcott, Chief Technology/Marketing Officer at Benzer Pharmacy charts out new pathways for improving the customer experience and sustaining business success through data-driven decision-making in support of independent pharmacists.   Patients of all ages are showing a greater desire for instant-access to healthcare information—something the digital transformation has made possible…

Spain Having largely recovered from the impact of the global financial crisis and with several impressive fundamentals in place, Spain once again stands as one of Europe’s premier healthcare and life science investment destinations.   These fundamentals include a revamped market access process that puts the Iberian nation on a par…

Korea Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision to base his clinical trials in Australia and provides his assessment of the future for oncology drug development in the…

France David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service provider leveraging agile solutions across the value chain. Lescuyer also shares his insights on the service sector and the most…

Turkey Turkey – home to an 80 million-strong population, a substantial pharmaceuticals market and a universal healthcare system that is the envy of its neighbours – stands as one of the most promising healthcare and life science investment destinations in its region. Topics covered in this report range from the successes…

GW Pharma Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are the producers of Sativex and Epiodiolex, the former being the world’s first prescription medicine derived from the cannabis plant —…

France The healthcare and life sciences industries, as they become more advanced and complex, increasingly require government involvement to ensure clinical compliance, ethical behaviour and the well-being of the nation. The health sector is subject to mounting regulatory pressures meaning politics must play a key role. As we advance more and more in healthcare…

Korea Bong Gil Nam, chairman and owner of Pharmbio Korea, offers his insights on his company’s importance in differentiating itself from the generic competitors in the market. Mr Nam also explains his strategy to expand into the East Asian market and provides his assessment on how established Korean pharmaceutical companies can…

USA 80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were approved in the USA in 2017, a record year and more than double the 40 approved in 2016.   Orphan drug spending grew from 5 to 10%…

Malaysia The growth of the Malaysian pharma market between 2006 and 2016. Pharmaceutical sales grew to over USD 2 billion by 2016, thanks in large part to a burgeoning prescription medicine segment.   The import and export of pharmaeuticals in Malaysia between 2006 and 2016. In 2016, the trade balance stood…